ANT3310 / Antabio - LARVOL DELTA

In vitro activity of meropenem–ANT3310 against clinical carbapenem-resistant Acinetobacter baumannii complex: phenotypic and genotypic characterisation (ESCMID Global 2026) - No abstract available

Preclinical

Potent activity of the novel combination Meropenem-ANT3310 against global OXA- and KPC-carbapenem-resistant Enterobacterales (CRE) clinical isolates from 2019 to 2023 (ESCMID Global 2026) - No abstract available

Clinical

Targeting metallo-β-lactamase endemicity: activity of novel meropenem-ANT3310 in combination with aztreonam against contemporary Enterobacterales (ESCMID Global 2026) - No abstract available

Combination therapy

In vitro activity of meropenem-ANT3310 and comparators against carbapenem-resistant Acinetobacter clinical isolates: implications for low- and middle-income countries (LMIC) (ESCMID Global 2026) - No abstract available

Preclinical

Pharmacokinetics-pharmacodynamics of ANT3310, in combination with meropenem, against carbapenem-resistant Acinetobacter baumannii using a neutropenic murine-pneumonia model (ESCMID Global 2026) - No abstract available

Combination therapy • PK/PD data • Preclinical • Infectious Disease • Pneumonia • Respiratory Diseases

Potent activity of the novel combination meropenem-ANT3310 against global Acinetobacter baumannii clinical isolates from 2019 to 2023 (ESCMID Global 2026) - No abstract available

Clinical

High-potency of the novel therapeutic combination meropenem/ANT3310 against KPC β-lactamase variants driving resistance to ceftazidime/avibactam (ESCMID Global 2026) - No abstract available

Pharmacokinetics, safety and tolerability of ANT3310 combined with meropenem in participants with impaired renal function (ESCMID Global 2026) - No abstract available

Clinical • PK/PD data

Meropenem-ANT3310: a novel agent targeting serine carbapenemase-producing Enterobacterales (ESCMID Global 2026) - No abstract available

Penetration of ANT3310 and meropenem into pulmonary epithelial lining fluid in healthy adult participants (ESCMID Global 2026) - No abstract available

Clinical

Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=26 | Completed | Sponsor: Antabio | Recruiting ➔ Completed

Trial completion

Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant Acinetobacter baumannii in Phase 1, 2, and 3 clinical trials. (PubMed, Expert Opin Investig Drugs) - "Specifically, 9 antibiotics are in Phase 1 (R-327, xeruborbactam/QPX-7728, upleganan/SPR-206, MRX-8, QPX-9003, zifanocycline/KBP-7072, apramycin/EBL-1003, zosurabalpin/RG-6006, and ANT-3310), two in Phase 2 (BV-100, OMN-6), and two in Phase 3 (zidebactam/WCK-5222, funobactam/XNW-4107) clinical trials...In particular, two monoclonal antibodies (TRL-1068, CMTX-101), a phage therapy (Phagebank), an immune-modulating agent (recombinant human plasma gelsolin/Rhu-pGSN), a microbiome-modulating agent (SER-155), and an engineered cationic antibiotic peptide (PLG-0206). Several agents with promising characteristics against CRAB infections are in clinical development (Phases 1, 2, and 3). The urgent need for therapeutic options against CRAB infections necessitates optimizing efforts and time for introducing successfully studied agents into clinical practice."

Journal • Review • Infectious Disease • GSN

Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects (clinicaltrials.gov) - P1 | N=41 | Completed | Sponsor: Antabio | Recruiting ➔ Completed

Trial completion • Renal Disease

Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=25 | Recruiting | Sponsor: Antabio | Not yet recruiting ➔ Recruiting

Enrollment open

Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=25 | Not yet recruiting | Sponsor: Antabio

New P1 trial

Evaluation of the activity of the novel antibiotic combination Meropenem-ANT3310 against recent multidrug-resistant Enterobacterales and Acinetobacter baumannii clinical isolates (ESCMID Global 2025) - No abstract available

Clinical • Late-breaking abstract

Pharmacokinetics/pharmacodynamics of ANT3310, in combination with meropenem, against carbapenem-resistant Enterobacterales using a neutropaenic murine acute pyelonephritis model (ESCMID Global 2025) - No abstract available

Combination therapy • PK/PD data • Preclinical • Nephrology

Disarming carbapenemase-producing Acinetobacter baumannii: high potency of the novel therapeutic combination of meropenem with the diazabyciclooctane beta-lactamase inhibitor ANT3310 (ESCMID Global 2025) - No abstract available

Broad spectrum coverage of serine β-lactamase and high in vitro potency against KPC- and OXA-48-like-producing Enterobacterales of meropenem in combination with the novel diazabyciccloctane β-lactamase inhibitor ANT3310 (ESCMID Global 2025) - No abstract available

Combination therapy • Preclinical

Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales. (PubMed, Antimicrob Agents Chemother) - "Minimum inhibitory concentration (MIC) values for ceftazidime, ceftazidime/avibactam, aztreonam, aztreonam/avibactam, aztreonam/nacubactam, cefiderocol, cefepime, cefepime/taniborbactam, cefepime/zidebactam, cefepime/nacubactam, imipenem, imipenem/relebactam, meropenem, meropenem/vaborbactam, meropenem/xeruborbactam, and meropenem/ANT3310 were determined by reference broth microdilution. Meropenem/ANT3310 (MIC50/MIC90 = 0.5/≥64 mg/L; 47/57 susceptible) and cefepime/taniborbactam (MIC50/MIC90 = 0.5/16 mg/L; 44/57 susceptible) also retained high levels of activity, although they were affected by NDM-type enzymes in combination with porin deficiency. Our findings highlight that cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, nacubactam, taniborbactam, zidebactam, xeruborbactam, and ANT3310 show promising activity against double-carbapenemase-producing Enterobacterales."

Journal

Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Antabio | Not yet recruiting ➔ Recruiting

Enrollment open • Renal Disease

Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Antabio

New P1 trial • Renal Disease

Evaluation of ANT3310 pharmacokinetics-pharmacodynamics, in combination with meropenem, using a dynamic in vitro infection model (ECCMID 2024) - No abstract available

Combination therapy • PK/PD data • Preclinical • Infectious Disease

Spontaneous frequency of resistance to meropenem/ANT3310 in carbapenem-resistant Enterobacterales and Acinetobacter baumannii (ECCMID 2024) - No abstract available

In vitro assessment of the novel antibiotic combination meropenem/ANT3310 against Gram-negative bacteria: CLSI Tier 1 study examining effects of varying MIC parameters and equivalency between agar dilution and broth microdilution methodologies (ECCMID 2024) - No abstract available

Gram negative • Preclinical • Infectious Disease